



MannKind Announces Positive New Market Survey Information Regarding AFRESA(R)

07/14/09

MannKind Announces Positive New Market Survey Information Regarding AFRESA(R)

VALENCIA, Calif.--(BUSINESS WIRE)--Jul. 14, 2009-- **MannKind Corporation (Nasdaq: MNKD)** today released new information related to the market potential for AFRESA, MannKind's ultra rapid-acting insulin.

In a market survey conducted in May 2009 involving 101 endocrinologists and 102 primary care physicians (all based in the United States) and utilizing MannKind's next generation inhaler, physicians expressed a preference for AFRESA for approximately 25% of both type 1 and type 2 patients that would qualify for use of AFRESA. Endocrinologists surveyed indicated a higher preference share for their type 2 patients (approximately 26%) than their type 1 patients (approximately 19%). Primary care physicians surveyed indicated a nearly equal preference share for their type 1 patients (approximately 26%) and type 2 patients (approximately 25%).

Alfred Mann, Chairman and Chief Executive Officer of MannKind, commented, "We are pleased with this latest survey conducted by a leading market research firm. While preference share does not translate directly into market share, this latest survey helps us to gauge physician intent in prescribing AFRESA in their clinical practices."

Dr. Peter Richardson, Corporate Vice President and Chief Scientific Officer, commented, "We believe that these results are a strong show of support for our next generation inhaler, which is not only smaller and easier to use, but also requires lower airflow, provides better cartridge emptying with one inhalation and requires less powder to deliver the same plasma insulin."

About AFRESA®

AFRESA is an ultra rapid-acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes. AFRESA is also the trade name for the product that MannKind has proposed to the FDA.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFRESA® and MKC253. MannKind has submitted an NDA to the FDA requesting approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MKC253 is currently in phase 1 clinical trials. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the market opportunities for MannKind's product candidates, that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks inherent in the generation and interpretation of market research, the progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, the manufacture of AFRESA, competition from other pharmaceutical or biotechnology companies, MannKind's ability to enter into any collaborations or strategic partnerships, intellectual property matters, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2008 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Source: MannKind Corporation

MannKind Corporation
Matthew Pfeffer

Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com